AUSTIN, TX and DURHAM, NC, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present at the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021.

Read this article:
Shattuck Labs to Present at H.C. Wainwright BioConnect 2021 Conference

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *